KRAS and non-small cell lung carcinoma: (2019) (74) conducted a retrospective analysis of 551 patients with advanced NSCLC with at least one oncogenic driver alteration (EGFR, KRAS, ALK, BRAF, ROS1, HER2, RET or MET) treated with immune checkpoint inhibitor (ICI) monotherapy in 24 centers from 10 countries.